Immuron provides update on U.S. clinical trials for Travelan and IMM-529

Immuron (ASX:IMC) has provided an update on its U.S. clinical programs for Travelan and IMM-529, confirming progress in its regulatory engagement with the U.S. Food and Drug Administration (FDA) and outlining next steps following minor protocol updates. …